Updated: January 18, 2026
Bumetanide Shortage Update: What Patients Need to Know in 2026
Author
Peter Daggett

Overview
Bumetanide supply disruptions affected patients through 2025. Here's the latest shortage update and what heart failure and kidney disease patients need to know in 2026.
Is Bumetanide in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Bumetanide near you.
If you take bumetanide for heart failure, kidney disease, or liver disease, you may have noticed it's been harder to find at the pharmacy in recent months. Supply disruptions to certain bumetanide formulations were confirmed in 2025, and while the situation has improved, patients need to stay informed and proactive heading into 2026.
What Happened: The 2025 Bumetanide Shortage
In mid-2025, confirmed supply disruptions hit certain bumetanide formulations. The most significantly affected was the 1 mg oral tablet — the most commonly prescribed strength — which faced manufacturing issues and increased demand. Healthcare authorities in both the US and UK confirmed the disruption, with limited stock anticipated through at least August 2025.
Injectable bumetanide formulations were also affected. In August and September 2025, several manufacturers including Novadoz reported shortages of specific injection strengths, while Fresenius Kabi and Hikma reported some availability. This created a patchwork of supply availability that varied significantly by pharmacy, region, and distributor.
Check live stock now.
Current Status: What's Available in 2026
By late 2025 and into 2026, the oral tablet supply for bumetanide improved for most strengths and regions. However, availability can still be inconsistent depending on:
Your geographic location and local distributor relationships
The specific strength you need (0.5 mg, 1 mg, or 2 mg)
Which manufacturer your pharmacy typically stocks
Whether you're seeking the oral tablet or injectable formulation
In short: most patients can now find bumetanide tablets with some searching, but don't assume your usual pharmacy has it. Check ahead of time.
Which Patients Were Most Affected?
Patients most impacted by the shortage include:
Those on bumetanide 1 mg tablets (the most commonly prescribed strength)
Hospitalized patients who require IV bumetanide (injectable shortage affected multiple manufacturers)
Patients with a furosemide allergy who specifically need bumetanide and cannot take the most common alternative
Patients with furosemide-resistant edema who rely on bumetanide's superior bioavailability
What Healthcare Providers Did During the Shortage
During the peak shortage period, guidance from healthcare organizations included:
Not starting new patients on affected bumetanide formulations
Switching stable patients to furosemide (40 mg furosemide ≈ 1 mg bumetanide) when no contraindications existed
Prioritizing remaining bumetanide stock for patients with furosemide allergies or intolerance
Counseling patients on daily weight monitoring to detect early signs of fluid retention during any medication transition
How to Protect Your Bumetanide Supply Going Forward
Even when the shortage is officially resolved, the underlying vulnerabilities in the generic drug supply chain remain. Here's how to stay protected:
Refill early. Don't wait until your last pill. Most insurance plans allow refills at 75–80% of days supply used.
Ask for a 90-day supply. A 90-day prescription reduces the number of times you need to find the medication and may be available via mail-order pharmacy.
Know your alternatives. Ask your doctor in advance: "If I can't find bumetanide, can we have a plan ready?" Having a backup prescription written and waiting can prevent a medical crisis.
Use medfinder. When your pharmacy doesn't have stock, medfinder can search pharmacies near you to find where bumetanide is available — saving you hours of calling.
Where to Check the Most Current Shortage Information
For the most current FDA drug shortage information, visit the FDA Drug Shortages database at accessdata.fda.gov. The ASHP (American Society of Health-System Pharmacists) also maintains a shortage database at ashp.org/drug-shortages. For help finding bumetanide at a pharmacy near you today, see our guide on why bumetanide is hard to find and what to do about it.
And if you can't find bumetanide at your local pharmacy today, medfinder can help you find it — we call pharmacies near you and text you the results.
Frequently Asked Questions
Certain bumetanide formulations — particularly 1 mg tablets and some injectable forms — faced confirmed supply disruptions in mid-2025. By 2026, supply has largely stabilized for oral tablets, but availability can still vary by pharmacy, region, and manufacturer. It's worth checking ahead of time before you run out.
The 1 mg oral bumetanide tablet and certain injectable formulations (0.25 mg/mL) were most affected by shortages in 2025. Multiple manufacturers including Novadoz reported injectable shortages, while Fresenius Kabi and Hikma maintained some supply. The 0.5 mg and 2 mg tablet formulations were sometimes more available.
Try these steps: use medfinder to search multiple pharmacies at once; call independent pharmacies, which may have different distributor relationships than chains; ask your pharmacist if a different strength is in stock; and contact your doctor to discuss a temporary alternative like furosemide if needed.
Visit the FDA Drug Shortages database at accessdata.fda.gov/scripts/drugshortages and search for 'bumetanide.' The ASHP Drug Shortages database at ashp.org/drug-shortages is another reliable real-time resource used by pharmacists and hospital systems.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Bumetanide also looked for:
More about Bumetanide
38,083 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.





